- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04052191
MCRcI® Stem Cell Treatment for Diffuse Coronary Artery Disease (MCRcI®)
March 29, 2024 updated by: Honya Medical Inc
Intra-Coronary Administration of MCRcI® (Myo-Cardial Regenerative Cellular Injection) Improves Left Ventricular Function in Patients With Diffuse Coronary Artery Disease
Safety evaluation of Intra-Coronary Administration of MCRcI® stem cells in Patients with Diffuse Coronary Artery Disease.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jackson TK Liu, MD
- Phone Number: +886921167980
- Email: honyamedical@gmail.com
Study Locations
-
-
-
Tainan, Taiwan, 74147
- HONYA Medical Inc
-
Contact:
- Jackson TK Liu, MD
- Phone Number: +88665055006
- Email: info@honyamedical.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with Diffuse Coronary Artery Disease
- Age 20~80
- Participants have received proper medication
- Canadian Cardiovascular Society class II- IV Angina.
Exclusion Criteria:
- Age <20 or >80
- Pregnant or breast feeding
- Positive adventitious infection (such as HIV, hepatitis )
- History of Myocardial Infarction within past 3 months
- Severe aortic or mitral valve narrowing
- Short of breath unable to receive PCI examination or treatment
- Malignant tumor
- Hematopoietic dysplasia
- Severe organ disease with less than 1 year of life expectancy
- Chronic kidney disease with CCr<20ml/min
- Kiney disease on renal dialysis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low Dose
Low Dose of MCRcI® stem cells.
|
Intra-Coronary Administration of MCRcI® stem cells
Other Names:
|
Experimental: Intermediate Dose
Intermediate Dose of MCRcI® stem cells.
|
Intra-Coronary Administration of MCRcI® stem cells
Other Names:
|
Experimental: High Dose
High Dose of MCRcI® stem cells.
|
Intra-Coronary Administration of MCRcI® stem cells
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment Emergent Adverse Events
Time Frame: 6 months
|
Number of adverse events
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left ventricle stroke volume
Time Frame: 12 months
|
Echocardiogram assessment on left ventricle stroke volume (volume of blood pumped from the left ventricle per beat (ml).
|
12 months
|
End diastolic volume
Time Frame: 12 months
|
Echocardiogram assessment on volume of blood in the left ventricle at the end of diastolic filling (ml)
|
12 months
|
Left ventricular ejection fraction (LVEF)
Time Frame: 12 months
|
Calculated by dividing the volume of blood pumped from the left ventricle per beat (stroke volume) by the volume of blood collected in the left ventricle at the end of diastolic filling (end-diastolic volume).
|
12 months
|
Severity of angina symptom using Canadian Cardiovascular Society grading.
Time Frame: 12 months
|
Canadian Cardiovascular Society grading of angina pectoris is a classification system used to grade the severity of exertional angina.
Scale ranges 0 ~ IV (most sever), with 0 Asymptomatic Angina, I Angina only with strenuous exertion, II Angina with moderate exertion, III Angina with mild exertion and IV Angina at rest.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Fang Y Lee, MD, Chang Gung Memorial Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 1, 2024
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
August 6, 2019
First Submitted That Met QC Criteria
August 8, 2019
First Posted (Actual)
August 9, 2019
Study Record Updates
Last Update Posted (Actual)
April 1, 2024
Last Update Submitted That Met QC Criteria
March 29, 2024
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KCG17121910001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on MCRcI® stem cells
-
Honya Medical IncChung Shan Medical UniversityCompletedMyocardial InfarctionTaiwan
-
Vitro Biopharma Inc.Not yet recruitingPitt Hopkins Syndrome
-
R-BioCompleted
-
University College, LondonUnknownTendinopathy | Achilles Tendinitis | Achilles Degeneration | Achilles Tendinitis, Right Leg | Achilles Tendon Thickening | Achilles Tendinitis, Left LegUnited Kingdom
-
StemCells, Inc.WithdrawnNeuronal Ceroid LipofuscinosisUnited States
-
Hadassah Medical OrganizationCompletedAmyotrophic Lateral Sclerosis
-
El-Rayadh Fertility CentreUnknownPremature Ovarian FailureEgypt
-
Samsung Medical CenterMedipost Co Ltd.Active, not recruitingBronchopulmonary DysplasiaKorea, Republic of
-
Medipost America Inc.Medipost Co Ltd.CompletedBronchopulmonary DysplasiaUnited States
-
Medipost Co Ltd.CompletedBronchopulmonary DysplasiaKorea, Republic of